Tackle infectious diseases and antimicrobial resistance
Infectious diseases are a major global health problem, accounting for one in five deaths worldwide and a quarter of the annual global disease burden (in terms of years of life lost due to premature mortality or physical disabilities).
Moreover, the annual global mortality associated with antimicrobial resistance is currently estimated at 5 million deaths. Alarmingly, it is expected to double and cost the global economy up to $100 trillion within the next 30 years according to the World Health Organization (WHO).
In light of this critical challenge, addressing this urgent issue and save lives, it is essential to have accurate and rapid diagnostic solutions to detect (drug-resistant) pathogens, which are essential for guiding treatment decisions and public health interventions. To meet this pressing need, the Deeplex engineering, developed by GenoScreen, has been specifically designed to achieve this goal with high precision and actionable results.
Get clinically actionable information from microbial DNA with the Deeplex engineering
Deeplex engineering combines deep multi-target DNA sequencing, automated bioinformatic analysis and easy reporting for microbial identification and extensive detection of drug resistance.
This innovative technology offers several key advantages:
- Culture-free: Can be performed directly from clinical specimens or isolates.
- Extensive: All-in-one design combining multiple drug resistance, bacterial speciation and strain genotyping targets, for extensive diagnosis and monitoring.
- Sensitive: Detection of minority variants and mixed infections.
- Fast: Results can be obtained within 2 days, starting from clinical samples.
- Accessible: Automated analytic tools and reporting; no need for bioinformatics skills.
- Cost-effective: Higher sample multiplexing than whole genome sequencing, no need for culturing (depending on bacterial load).
Deeplex engineering: powerful solutions for clinicians and researchers
By overcoming major limitations of conventional phenotypic and molecular testing, Deeplex products represent novel, rapid, and comprehensive powerful solutions for significantly improving the clinical management, early detection, and real-time monitoring of drug-resistant infectious diseases worldwide.